研究单位：[1]Allergan[2]Xuanwu Hospital Capital Medical University Beijing,Beijing,China,100053[3]Peking University Third Hospital Beijing,Beijing,China,100191[4]Beijing Tongren hospital Capital Medical University Beijing,Beijing,China,100730[5]Zhongshan Ophthalmic Center,Sun Yat-Sen University Guangzhou,Guangdong,China,510060[6]Tongji Hospital of Tongji Medical College,Huazhong University of Science & Technology Wuhan,Hubei,China,430030[7]Second Xiangya Hospital of Central South University Changsha,Hunan,China,410011[8]Jiangsu Province Hospital Nanjing,Jiangsu,China,210029[9]Eye & ENT Hospital of Fudan University Shanghai,Shanghai,China,200031[10]West China Hospital,Sichuan University Chengdu,Sichuan,China,610041[11]Tianjin Eye Hospital Tianjin,Tianjin,China,300020[12]Tianjin Medical University Eye Hospital Tianjin,Tianjin,China,300384[13]The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou,Zhejiang,China,310009[14]Eye Hospital of Wenzhou Medical University Wenzhou,Zhejiang,China,325027[15]Henan Provincial Eye Hospital Henan,Zhengzhou,China,450003
研究目的：
A study to evaluate the long-term safety of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) in Chinese patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blocker or prostaglandin analogues.
